A biohealth company specializing in early detection of brain diseases like dementia has established a presence in Jeju Island. The company utilizes blood tests and other methods to identify individuals at risk. This venture represents a significant 1 billion won (approximately $750,000 USD) investment over three years. The move aims to leverage Jeju’s business-friendly environment and foster innovation in preventative healthcare. Early diagnosis is crucial for managing dementia and improving patient outcomes. This initiative hopes to contribute to a future where dementia is less debilitating through timely intervention. The company’s technology offers a promising approach to addressing the growing global concern of age-related cognitive decline.